Last reviewed · How we verify
NCT03935984
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Phase 4 trial testing Calcitonin in Primary Hyperparathyroidism in 37 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Joseph Sferra |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 37 |
| Start date | 29 May 2019 |
| Primary completion | 1 June 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Calcitonin (CALCITONIN) — full drug profile →
Conditions studied
- Primary Hyperparathyroidism — all drugs for Primary Hyperparathyroidism →
- Hypercalcemia — all drugs for Hypercalcemia →
Sponsor
Joseph Sferra
Who can join
18 and older, any sex, with Primary Hyperparathyroidism or Hypercalcemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03935984
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Calcitonin
Trials testing the same drug.
- NCT05805683 — Calcitonin Therapy on Incidence and Severity of Neuropathic Pain After Spinal Cord Injury · NA · recruiting
- NCT03342001 — Hypothyroidism Treated With Calcitonin · Phase 4 · completed
Other recruiting trials for Primary Hyperparathyroidism
Currently open trials in the same condition.
- NCT07444723 — Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors · Phase 2, PHASE3 · recruiting
- NCT06859580 — Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism · Phase 4 · recruiting
- NCT05997810 — Parathyroid Tumor Clonal Status · recruiting
- NCT05761743 — Glycemic Control, Type II Diabetes, Parathyroidectomy · active not recruiting
- NCT07138820 — 18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03935984 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Joseph Sferra
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03935984.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing